《40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"》
LLY 是行业龙头，基本面强劲；尽管显著的盈利增长压缩了其市盈率，该股在历史上仍属昂贵。
来看看礼来股票过去一年的表现。这只股票在很大程度上、并在许多方面已成为制药行业的基准。在此期间股价上涨了约50%，但自约一个月前创下历史新高以来已下跌超过10%。
to take a look at the performance of Eli Lilly's stock over the past year. This stock has largely, and in many ways, become the benchmark for the pharmaceutical industry. Stocks rose by about 50% during this period, but have fallen by more than 10% since reaching their all-time high about a month ago.